Insilico Medicine Nominates ISM9077 as Preclinical Candidate

Insilico Medicine has advanced ISM9077, a potential first-in-class target Y inhibitor, to the preclinical candidate (PCC) stage for the treatment of ocular diseases, inflammatory disorders, and aging. This candidate is part of the company's "pipeline-in-a-drug" approach, aiming to develop a single molecule for multiple conditions.

The drug candidate ISM9077 was designed, evaluated, and optimized using Insilico Medicine's generative AI platform, Chemistry42. The company states that this technology significantly accelerates the discovery process for new drug candidates.

Insilico Medicine's strategy centers on leveraging artificial intelligence across various stages of drug development, with the goal of bringing new therapies to patients more rapidly. The company has previously reported progress on other AI-discovered drug candidates advancing into clinical trials.

Achieving preclinical candidate status is a significant milestone, typically preceding extensive safety and efficacy studies required before human clinical trials can commence.